

1
2
3 **Prevalence of Seropositive VDRL cases amongst pregnant women at the Rivers State**
4 **University Teaching Hospital, Nigeria: Is routine screening for Syphilis using VDRL still**
5 **relevant?**

6
7 **Abstract:**

8 **Background:** Untreated maternal syphilis is strongly associated with adverse birth outcomes. The WHO
9 recommends routine serological screening in pregnancy. Some workers have advised a reappraisal of this
10 practice, having demonstrated low seroprevalence in their antenatal population.

11 **Objective:** To determine the prevalence of seropositive VDRL cases amongst pregnant women at the
12 Rivers State University Teaching Hospital (RSUTH) in order to justify the need and cost-effectiveness for
13 continued routine syphilis screening using VDRL alone.

14 **Methodology:** A retrospective review of hospital and laboratory records of all pregnant women booked
15 for antenatal care (ANC) at RSUTH in a two-year period, from May 2017 to April 2019, was carried out.
16 Data on patients' age, parity and educational level, and reactivity of VDRL test at booking were retrieved
17 using structured pro-forma and analyzed using Epi Info Version 7. Test for significance using Chi-square
18 was set at significant level of $P < 0.05$.

19 **Results:** 3560 clinic patients had VDRL screening out of which 63 were positive. The overall prevalence
20 rate in this study was 1.8%. The mean age was 31.5 ± 4.7 years and the mean gestational age at booking
21 was 22.1 ± 6.8 weeks. There was no significant relationship between their age ($\chi^2 = 0.403$, **p-**
22 **value=0.940**), parity ($\chi^2 = 3.707$, **p-value=0.0.157**), and educational status ($\chi^2 = 1.853$, **p-**
23 **value=0.396**), and seropositivity. The cost of VDRL test per patient in RSUTH is \$3, to detect the 63
24 cases the sum of \$10,680 was spent.

25 **Conclusion:** The seroprevalence rate of syphilis in this study was low. Initial screening using VDRL
26 alone is neither justified nor cost effective. Selective screening based on risk factors and specific test with
27 TPHA is recommended.

28
29 **Key Words:** VDRL, syphilis screening, prevalence, determinants, pregnancy, Rivers State,

30 **Introduction:**

31 Maternal syphilis is an important cause of adverse pregnancy outcome [1]. Syphilis, caused by infection
32 with *Treponema pallidum*, is a muco-cutaneous sexually transmitted infection (STI) with high infectivity
33 in the early stages. It may also be passed trans-placentally to the baby from the ninth week of gestation
34 onwards [2]. Untreated maternal syphilis is strongly associated with adverse birth outcomes including
35 increased incidence of stillbirths, low birth weight and premature live births compared with uninfected
36 women [3]. Congenital syphilis infection can result in serious complication in surviving newborns,
37 including central nervous system abnormalities, deafness, multiple skin, bone and joint abnormalities and
38 haematological disorders [1].

39 The WHO recommend serological test for syphilis in pregnancy and treatment with injectable penicillin,
40 including the partner, as a routine part of antenatal care [4]. Ideally this screening should be done in the
41 first trimester or at first antenatal visit and again early in the third trimester. Syphilis screening and

42 treatment in the antenatal care is an effective way to reduce fetal and infant mortality and morbidity in the
43 developing world.

44 The seropositive rate among pregnant women reported in Nigeria in the last five decades has been put at
45 <3% [5, 6, 7, 8], while generally in Africa, the figure is in the range of 3%-18% [9, 10, 11]. While
46 syphilis during pregnancy in the western world today is rare [12, 13] largely due to effective antenatal
47 screening, maternal syphilis remains a problem in many countries of sub-Saharan Africa [9, 11]. In a
48 previous retrospective study at our center over a ten-year period, 2004-2013, involving 12,971 patients,
49 the prevalence was put at 7.28% [14]. No confirmatory test was done then, as it is not done now. That was
50 quite some time ago and needs to be revalidated.

51 Most individuals with syphilis are asymptomatic or have transient lesions, and serological tests are often
52 the preferred method for detection [15, 16]. The VDRL test is a slide flocculation test employed in the
53 diagnosis of syphilis and is the most widely used. The antigen used in this test is cardiolipin, which is a
54 lipoidal extracted from beef heart, while the specific test is the *Treponema pallidum* haemagglutination
55 (TPHA) test. Any reactive VDRL test must be crosschecked with a specific treponemal test, Cardiolipin
56 VDRL tests are not truly specific for syphilis. Antibody concentrations may be high in a large number of
57 unrelated diseases, pregnancy and as a normal variant in some healthy people.

58 The TPHA is more sensitive than the VDRL in all but the primary syphilis and it is the most sensitive test
59 of all for latent disease. These specific tests are not widely available in developing countries because they
60 are laboratory dependent and require trained personnel; refrigeration for storage of reagents, and
61 electricity to run its equipment [15, 16]. Furthermore, the results might take days to weeks to be available.

62 The practice of universal antenatal screening for syphilis has been advised. Some workers have however
63 advised a reappraisal of the practice having demonstrated low seroprevalence in their antenatal
64 population. They questioned the cost effectiveness of this practice given its low yield [17, 18].

65 This study therefore, seeks to determine the prevalence of seropositive VDRL cases amongst pregnant
66 women at the RSUTH in order to justify the need and cost-effectiveness for continued routine syphilis
67 screening using VDRL alone as practiced.

68 **Methodology:**

69 A retrospective, quantitative study of hospital and laboratory records of all pregnant women booked at the
70 RSUTH for antenatal care in a two years period (1ST May 2017 to 30TH April 2019) was carried out. The
71 study period of two years was chosen as it marked the period of conversion of the former Braithwaite
72 Memorial Specialist Hospital (BMSH) to the RSUTH and is the expected period of child spacing, to limit
73 duplication of cases.

74 Data on patients' age, parity and educational status and reactivity of VDRL test (positive or negative) at
75 booking were retrieved using structured pro-forma. The case records of all seropositive cases were also
76 followed up to determine fetal outcome at delivery, note was made of any stillbirth, prematurity, low birth
77 weight, and gross CNS or musculoskeletal abnormality, usually included in the delivery summary notes.
78 **Two Interns were trained on the structured pro-forma and assisted in the data collection.** The age was

79 categorized into ≤ 19 years, 20-29 years, 30-39 years and ≥ 40 years. The parity was categorized into
80 nullipara (para 0), multipara (para 1-4) and grand multipara (para ≥ 5).

81 All pregnant women who registered for antenatal care during the study period and who did a VDRL test
82 and their result entered in the laboratory records were included, those with incomplete records were
83 excluded, and a formal sample size was not calculated. There were 3560 cases that met the stated criteria
84 and formed the study population.

85 Data were analyzed using United States CDC Epi Info Version 7. Data were summarized using
86 frequencies and proportions for categorical variables; and means, standard deviation, medians and range
87 employed for quantitative variables. The test of significance for the categorical and discrete variables was
88 done using Chi-square at statistically significant level of $P < 0.05$.

89 The RSUTH is one of two tertiary hospital for referral from all private clinics, maternity homes, primary
90 health centers and secondary health facilities from all the 23 Local government areas of Rivers State,
91 Nigeria. The hospital is funded by the Government and patients are expected to pay directly for services
92 (except few that participate in the National Health Insurance Scheme). The Department of Obstetrics and
93 Gynaecology runs antenatal clinics Mondays through Fridays. It provides emergency obstetric services to
94 women referred from other centers, as well as providing antenatal care and delivery services for low and
95 high-risk pregnant women booked with the hospital. The Hospital attends to about 2000 bookings
96 annually, with over 1500 deliveries per annum. The hospital is well equipped and has availability of
97 qualified team comprising of Obstetricians, Pediatricians and Anaesthetist. There is availability of
98 laboratory and blood bank services in the hospital.

99 At the Laboratory, all serum samples, test antigens, and control samples were brought to room
100 temperature (26°C) and tested using the VDRL test kit, Rapid Diagnostics by DiaSpot[®] from Indonesia. A
101 confirmatory test using TPHA for all positive VDRL sera is not routinely done in our setting. The cost of
102 VDRL test per patient in RSUTH is N1000 naira, at official conversion rate of N335 to \$1, that is
103 approximately \$3.

104 Results:

105 During the study period, 3560 antenatal clinic patients had VDRL screening out of which 63 were
106 positive. The overall prevalence rate in this study was 1.8%, declining from 2.0% in 2017 to 1.5% in 2018
107 (table 1). The ages of the patients ranged from 15-48 years with a mean age of 31.5 ± 4.7 years and a mean
108 gestational age at booking of 22.1 ± 6.8 weeks and the modal parity was 3. Table 2 and Figure 1 shows the
109 distribution of sociodemographic characteristic of the clinic attendees.

110
111
112
113
114
115
116

Table 1: Prevalence of Positive VDRL cases among Clinic Attendees (n=3560):

Year	Positive (n/%)	Negative (n/%)	Total
------	----------------	----------------	-------

2017	36 (2.0)	1722 (98.0)	1758
2018	27 (1.5)	1775 (98.5)	1802
Overall	63 (1.8)	3497 (98.2)	3560

117
118
119
120

Table 2: Pattern of socio-demographic distribution of the clinic attendees (n=3560):

Characteristics	Frequency (N)	Percentage (%)
1. Age group		
≤19 years	42	1.2
20-29 years	1137	31.9
30-39 years	2216	62.2
40 years and above	165	4.6
Total	3560	100.0
Mean age ± Standard deviation		31.5±4.7
2. Parity		
Nullipara	1125	32.4
Multipara	2326	65.3
Grand multipara	79	2.2
Total	3560	100.0
Modal Parity = 3.		
3. Educational qualification		
Primary	58	1.6
Secondary	922	25.9
Tertiary	2580	72.5
Total	3560	100.0

121
122
123
124





Figure 1: Frequency distribution of socio-demographic characteristics of the attendees

The majority (about two-thirds) of positive cases was seen in the age group 30-39 years, Multipara group and Tertiary education group (Figure 2 and Table 3). However, on Chi square analysis of the Socio-demographic characteristics and serum-reactivity of VDRL, there was no statistically significant relationship between their age ($\chi^2 = 0.403$, $p\text{-value}=0.940$), parity ($\chi^2 = 3.707$, $p\text{-value}=0.0.157$), and educational Status ($\chi^2 = 1.853$, $p\text{-value}=0.396$) distribution and seropositivity. There was no documentation of treatment offered in all 63 cases and there was no specific or confirmatory test done on any of these patients. None of them had stillbirth, premature delivery, low birth weight babies and their babies at delivery did not show any features of congenital syphilis.



139
140 **Fig. 2: Prevalence of VDRL by Age, Parity and Education among the clinic Attendees.**

141
142
143 **Table 3: Prevalence and Determinants of Positive VDRL cases among the Clinic Attendees:**

Characteristics	VDRL		Total	Chi-square	df	p-value
	Positive (n/%)	Negative (n/%)				
Age group				0.403	3	0.940
10-19 years	1 (2.4)	41 (97.6)	42			
20-29 years	18 (1.6)	1121 (98.6)	1137			
30-39 years	41 (1.9)	2175 (98.1)	2216			
40 years and above	3 (1.8)	162 (98.2)	165			
Parity				3.707	2	0.157
Nullipara	15 (1.3)	1140 (98.7)	1155			
Multipara	45 (1.9)	2281 (98.1)	2326			
Grand multipara	3 (3.8)	76 (96.2)	79			
Educational qualification				1.853	2	0.396
Primary	1 (1.7)	57 (98.3)	58			
Secondary	21 (2.3)	901 (98.0)	922			
Tertiary	41 (1.6)	2539 (98.4)	2580			

145 **Discussion:**

146 The seroprevalence of syphilis screening with VDRL of 1.8% found in this study is low. This figure is
147 within the range of 0.6% - 2.3% reported over the last five decades in Nigeria [5, 6, 8] and in other
148 African Countries [9, 10, 11]. This is however, higher than the prevalence of 0.05% reported in
149 Maiduguri, Northern Nigeria [7], but significantly much less than 7.28% earlier reported in our center
150 [14] and 10% prevalence reported in Oshogbo, Western Nigeria [19]. This implies that the prevalence of
151 syphilis in Nigeria has been on a decline, and it is buttressed by the year on year decrease in the
152 prevalence in this study of 2.0% in 2017 and 1.5% in 2018. Similarly, the results of previous study in
153 Enugu, Nigeria on VDRL screening in pregnancy by Ikeme and Okeke [20] strongly showed a continuing
154 very low prevalence rates of syphilis (3.06%, 1.3%, 0.125%).

155 The low prevalence found in this study, and indeed the declining prevalence rates across the country, may
156 be attributable to less risky sexual behavior, interventions to control HIV/AIDS, widespread availability
157 of antibiotics and introduction of syndromic management of STIs.

158 The value of the VDRL test lies in its low cost and ease of titration, however, there is a very high false-
159 positive result rate associated with its use. More specific test like TPHA are needed to exclude false
160 positive cases. Biological false positivity of 0.02 to 0.7% were reported by various studies in Nigeria [7,
161 21]. In our study population, confirmatory tests were not done due to non-availability of test kits, and we
162 could not ascertain the number of false positive cases.

163 The highest proportion of positive results (41/63) was recorded in the 30-39 years, giving a prevalence of
164 positive cases of 65% in this group; followed by the 20-29 years (18/63) with prevalence of 28.6%. This
165 similar to the findings of the previous study at our Centre [14] and of Bukar M et al [7] in Maiduguri,
166 Northern Nigeria. This could be due to the higher sexual activity in this group which therefore make them
167 more vulnerable to risk of acquiring infections. The difference in the relationship of age groups and
168 seropositivity in this study was however not statistically significant at $p < 0.05$.

169 The mean gestational age at booking in our center was 22.1 weeks. This suggests that most women book at
170 a time when the effect of syphilis on the fetus would have occurred and late detection of syphilis would
171 have little effect on the overall outcome of the pregnancy. Early booking and screening are essential in
172 preventing congenital syphilis. There was no documentation of treatment offered in all 63 cases and there
173 were no reports of congenital syphilis in the babies of the mothers.

174 The estimated cost of VDRL, at N1000 in RSUTH, is \$3; meaning about N3, 560, 000 (\$10, 680) was
175 spent to detect the 63 VDRL positive cases. In our society, more than a third of the population live in
176 extreme poverty, and diseases such as anaemia, malaria and malnutrition are still highly prevalent. These
177 are certainly more important reproductive health issues than syphilis.

178 Limitations of the study:

179 This study may be limited by the fact that it is a retrospective study and there might be inaccuracies in the
180 documented data such as the treatment of positive cases and the effects of congenital syphilis on the
181 babies, especially as they were not followed up through childhood. The study is also hospital based and
182 may not reflect what happens in the general population in the state, as some pregnant women do not
183 access the tertiary institution services.

184

185 **Conclusion:**

186 The seroprevalence rate of syphilis in this study was low, and due to the overall low sensitivity of the
187 VDRL test, initial screening in our center using VDRL alone is neither justified nor cost effective.
188 Selective screening based on risk factors, like younger age, and specific test with TPHA is recommended.

189 **Ethical Approval and Consent:**

190 As the study involved review of existing MCH records, ethical approval, and a waiver for informed
191 consent, was obtained from the Ethics and Research Committee of the RSUTH.

192 **Source of Support:** Nil

193 **Conflict of Interest:** None

194 **References:**

- 195 1. US Preventive Service Task Force. Screening Syphilis Infection: Recommendation Statement.
196 Ann Fam Med 2004; 2: 362-365.
- 197 2. Lewis DA, Young H. Syphilis. Sex Transm Inf. 2006; 82: iv13-iv15.
- 198 3. Watson-Jones D, Oliff M, Terris-Prestholt F, et al. Antenatal syphilis screening in sub-Saharan
199 Africa: lessons learned from Tanzania. Trop Med Int Health 2005; 10: 934-943.
- 200 4. World Health Organization. Guidelines for the management of Sexually Transmitted Infections.
201 2001. World Health Organization, Geneva.
- 202 5. Osoba AO. Serological test for syphilis among hospital patients in Ibadan, 1968-1970.
203 Proceedings of the first medical research seminar, Fifty years of medical research in Nigeria, 1-4
204 February 1972. Yaba, Lagos: Academic Press; 1972: 49-52.
- 205 6. Ekele BA, Bello CSS. Sero-reactivity amongst pregnant women screened for syphilis at Jos
206 University Teaching Hospital. Niger J Med 1997; 6: 11-13.
- 207 7. Bukar M, Audu BM, Takai UI, Ajayi BB, Kullima AA. Is routine antenatal screening for syphilis
208 in Nigeria still justified clinically and economically? Saudi Med J. 2009; 30: 1311-15.
- 209 8. Nwosu BO, Eleje GU, Obi-Nwosu AL, Ahirakwem IF, Akujobi CN, Egwuatu CC et al. Is
210 routine venereal disease research laboratory test still justified? International Journal of Women's
211 Health 2015; 7: 41-46. Available at <https://doi.org/10.2147/IJWH.S70442>.
- 212 9. Hira S, Ratnam A, Bhat G, et al. Congenital syphilis in Lusaka-11. Incidence at birth and
213 potential risks among hospital delivered infants. East Afr Med J. 1982; 59: 306-308.
- 214 10. Azeze B, Fantahun M, Kidan KG, Haile T. Seroprevalence of syphilis among pregnant women
215 attending antenatal clinics in a rural hospital in north west Ethiopia. Genitourin Med. 1995; 71:
216 347-350.
- 217 11. Hira SK, Bhat GJ, Chikamata DM. Syphilis intervention in pregnancy: Zambian demonstration
218 project. Genitourin Med. 1990; 66: 159-164.
- 219 12. Skarpass T, Loe K. The occurrence of positive serological syphilis reactions in pregnant women
220 in Norway 1964-1978. *Tidsskr Nor Laegeforen*. 1980; 100: 1840-43.
- 221 13. Klass P, Brown E, Pelton S. The incidence of prenatal syphilis at the Boston City Hospital: a
222 comparison across four decades. Paediatrics. 1994; 94: 24-28.
- 223 14. Iyalla C, Omunakwe H, Okoh DA. A retrospective study of the seroprevalence of antibodies to
224 HbsAg, HIV-1/2 and Syphilis amongst pregnant women at booking in a tertiary hospital in Port
225 Harcourt, Southern Nigeria. IOSR Journal of Dental and Medical Sciences. 2016; 15(6): 86-92.
226 Available at <https://doi.org/10.9790/0853-1506028692>.
- 227 15. World Health Organization. The Global Elimination of Congenital Syphilis: Rational and
228 Strategy for Action. 2007; WHO, Geneva. Available at
229 http://whqlibdoc.who.int/publications/2007/9789241595858_eng.pdf. Accessed October 2019.

- 230 16. WHO/TDR. Sexually Transmitted Diseases Diagnostic Initiative, Evaluation of rapid diagnostic
231 tests: syphilis. *Nat Rev Microbiol.* 2006; 4(Suppl 12): S33-S40.
- 232 17. Olubukola A. Adesina O. Routine Antenatal Syphilis Screening in South-West Nigeria – A
233 questionable practice. *Annals of Ibadan Postgraduate Medicine* 2010; 8: 1. Available at
234 <http://dx.doi.org/10.4314/aipm.v8i1.63952>.
- 235 18. Obisesan KA, Ahmed Y. Routine antenatal syphilis screening – A case against. *Afr J. Med. Med.*
236 *Sci.* 1999; 28: 185-187.
- 237 19. Ojo DA, Oyetunji IOA. Seroprevalence of syphilis among pregnant women in Oshogbo in
238 southwestern Nigeria. *ASSET Series B.* 2007; 6(1): 61-65.
- 239 20. Ikeme AC, Okeke TC. The prevalence of VDRL as routine test for pregnant women: a critical
240 study. *Niger J Clin Pract* 2006; 9: 65-7.
- 241 21. Taiwo SS, Adesiyi YO, Adekanle DA. Screening for syphilis during pregnancy in Nigeria: a
242 practice that must continue. *Sex Transm Infect* 2007; 83: 357-9.

243
244
245

UNDER PEER REVIEW